HDL-c is a powerful lipid predictor of cardiovascular diseases

被引:41
作者
Bruckert, E. [1 ]
Hansel, B. [1 ]
机构
[1] Hop La Pitie Salpetriere, Inst Endocrinol & Prevent Cardiovasc Dis, AP HP, F-75651 Paris 13, France
关键词
D O I
10.1111/j.1742-1241.2007.01509.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Relationship between HDL-c and cardiovascular diseases: Beyond the role of low-density lipoprotein cholesterol (LDL-c) in the development of atherosclerosis, growing evidence suggest that high-density lipoprotein cholesterol (HDL-c) is a powerful predictor of cardiovascular disease. Indeed, epidemiological, mechanistic and intervention studies suggest that low HDL-c is a major cardiovascular risk factor and that increasing HDL-c plasma levels may be beneficial, particularly in patients with low HDL-c levels. The inverse association between HDL-c concentrations and cardiovascular risk is continuous without threshold value. Thus, any categorical definition of low HDL-c is arbitrary. Protective effects of HDL: HDL particles are highly heterogeneous in structure and intravascular metabolism. Antiatherogenic properties of HDL include its role in the reverse cholesterol transfer, besides its antioxidant, anti-inflammatory and antiapoptotic activities. What should clinicians do? From a practical point of view, HDL-c should be systematically measured to assess the cardiovascular risk in patients. The first step to consider in subjects with low HDL-c is to look for specific causes and give advice to change inappropriate lifestyle components associated with low HDL-c, such as smoking, lack of physical exercise and overweight. Patients with very low HDL-c need a thorough evaluation by specialist physicians. Statins are associated with a modest increase of HDL-c (5%) while fibrates and nicotinic acid increase HDL-c by 10% and 20% respectively. © 2007 The Authors.
引用
收藏
页码:1905 / 1913
页数:9
相关论文
共 44 条
[11]   COMPARISON OF THE EFFICACY OF SIMVASTATIN AND STANDARD FIBRATE THERAPY IN THE TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA AND COMBINED HYPERLIPIDEMIA [J].
BRUCKERT, E ;
DEGENNES, JL ;
MALBECQ, W ;
BAIGTS, F .
CLINICAL CARDIOLOGY, 1995, 18 (11) :621-629
[12]   The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I-Milano [J].
Bruckert, E ;
vonEckardstein, A ;
Funke, H ;
Beucler, I ;
Wiebusch, H ;
Turpin, G ;
Assmann, G .
ATHEROSCLEROSIS, 1997, 128 (01) :121-128
[13]   High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients [J].
Bruckert, E ;
Baccara-Dinet, M ;
McCoy, F ;
Chapman, J .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) :1927-1934
[14]   CIPROFIBRATE THERAPY NORMALIZES THE ATHEROGENIC LOW-DENSITY-LIPOPROTEIN SUBSPECIES PROFILE IN COMBINED HYPERLIPIDEMIA [J].
BRUCKERT, E ;
DEJAGER, S ;
CHAPMAN, MJ .
ATHEROSCLEROSIS, 1993, 100 (01) :91-102
[15]   Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy [J].
Cannon, Christopher P. ;
Steinberg, Benjamin A. ;
Murphy, Sabina A. ;
Mega, Jessica L. ;
Braunwald, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) :438-445
[16]   Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease [J].
Chapman, M. John .
PHARMACOLOGY & THERAPEUTICS, 2006, 111 (03) :893-908
[17]   Effects of rosuvastatin, atorvastatin, simvastatin, and prarvastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome [J].
Deedwania, PC ;
Hunninghake, DB ;
Bays, HE ;
Jones, PH ;
Cain, VA ;
Blasetto, JW .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (03) :360-366
[18]   Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice [J].
Franceschini, G ;
Calabresi, L ;
Chiesa, G ;
Parolini, C ;
Sirtori, CR ;
Canavesi, M ;
Bernini, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (05) :1257-1262
[19]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[20]   FAMILIAL HYPER-ALPHA-LIPOPROTEINEMIA - STUDIES IN 18 KINDREDS [J].
GLUECK, CJ ;
FALLAT, RW ;
MILLETT, F ;
GARTSIDE, P ;
ELSTON, RC ;
GO, RCP .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1975, 24 (11) :1243-1265